Poznan/Hannover (ots) - Jens Ocksen, Vorstandsvorsitzender Volkswagen Poznan, eröffnet Festveranstaltung im ...
Grünenthal will present latest news and experiences of the targeted topical treatment of postherpetic neuralgia (PHN) at the EFIC congress, October 9 - 13, 2013 in Florence, Italy
Aachen (ots) - Healthcare professionals who would like to know more about the targeted topical treatment of postherpetic neuralgia (PHN) are invited to join the Meet-the-Expert sessions at the Grünenthal booth at the EFIC congress, October 9 - 13, 2013 in Florence, Italy. PHN is a chronic disabling pain condition usually characterized by burning, stabbing, shooting pain caused by a previous herpes zoster infection (commonly known as shingles). At the Meet-the-Expert sessions participants will understand what it means to "think outside the pill box" and learn more about the importance of a well- tolerated and effective long-term treatment for chronic PHN. To get more information about the international speakers, the congress and to see the full program of the Meet-the-Expert sessions, please visit www.versatis.com.
EMBARGO: This information is for Healthcare professionals only.
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation. Grünenthal is one of the last remaining five research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. The research and development costs amounted to a preliminary of about 26 percent of revenues in 2012. Grünenthal's research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies. Altogether, the Grünenthal Group has affiliates in 26 countries worldwide. Grünenthal products are sold in more than 155 countries and today approx. 4,400 employees are working for the Grünenthal Group worldwide. In 2012, Grünenthal achieved preliminary revenues of EUR 973 mn. More information: www.grunenthal.com.
Jeanette Hübsch, Senior Manager Versatis, Grünenthal Europe &
Phone: +49 241-569-1487, email: email@example.com